ArticleTranslational lung cancer research2021
Can autoantibody tests enhance lung cancer screening?-an evaluation of EarlyCDT
Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2022Pooled it
- Impact of low-dose computed tomography (LDCT) screening on lung cancer-related mortality.The Cochrane database of systematic reviews · 2022Pooled it
- Circulating tumor-associated autoantibody signatures for diagnosis and prognosis in small-cell lung cancer and lung adenocarcinoma.British journal of cancer · 2026Article
- Liquid biopsy biomarkers for cancer detection, treatment monitoring, and clinical outcome prediction.Frontiers in cell and developmental biology · 2026Review
- Multiple Tumor-related autoantibodies test enhances CT-based deep learning performance in diagnosing lung cancer with diameters < 70 mm: a prospective study in China.BMC pulmonary medicine · 2025Article
- Upfront blood microRNA test in LDCT-reluctant individuals: insights from the biomild trial.Journal of experimental & clinical cancer research : CR · 2025Article
- Emerging Strategies in Lung Cancer Screening: Blood and Beyond.Clinical chemistry · 2024Review
- Lung cancer risk discrimination of prediagnostic proteomics measurements compared with existing prediction tools.Journal of the National Cancer Institute · 2023Article
- Circulating proteome for pulmonary nodule malignancy.Journal of the National Cancer Institute · 2023Article
- Assessment of the EarlyCDT-Lung test as an early biomarker of lung cancer in ever-smokers: A retrospective nested case-control study in two prospective cohorts.International journal of cancer · 2023Article
- Temporal reproducibility of IgG and IgM autoantibodies in serum from healthy women.Scientific reports · 2022Article
- The combination of a seven-autoantibody panel with computed tomography scanning can enhance the diagnostic efficiency of non-small cell lung cancer.Frontiers in oncology · 2022Article
- The role of autoantibody detection in the diagnosis and staging of lung cancer.Annals of translational medicine · 2021Article
- Seven tumor-associated autoantibodies as a serum biomarker for primary screening of early-stage non-small cell lung cancer.Journal of clinical laboratory analysis · 2021Article
- Personalising lung cancer screening: An overview of risk-stratification opportunities and challenges.International journal of cancer · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTumor-associated autoantibodies are considered promising markers for early lung cancer detection; so far, however, their capacity to detect cancer has been tested mostly in a clinical context, but not in population screening settings. This study evaluates the early detection accuracy, in terms of sensitivity and specificity, of EarlyCDT
methodsThe EarlyCDT
resultsIn the case group, the test panel showed a sensitivity of only 13.0% (95% CI: 4.9-26.3%). Specificity was estimated at 88.9% (95% CI: 80.5-94.5%) in the baseline control group, and 91.1% (95% CI: 83.2-96.1%) among controls presenting CT-detected nodules.
conclusionsThe test panel showed insufficient sensitivity for detecting lung cancer at an equally early stage as with low-dose computed tomography screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.